Indivior surges on Q4 earnings beat, $400M buyback launch
SUBLOCADE revenue jumps 30% as opioid treatment maker expands shareholder returns with new repurchase program
Indivior shares climbed in Thursday trading after the pharmaceutical company reported fourth-quarter earnings that handily exceeded analyst expectations, accompanied by a new $400 million share repurchase program and record revenue from its flagship opioid treatment.
The company reported non-GAAP earnings per share of $0.82 for the quarter ended December 31, 2025, surpassing the consensus estimate of $0.67, while revenue reached $358 million compared to analyst projections of $305.6 million, according to the company's earnings release. The performance marks a significant turnaround for the specialty pharmaceutical company, which has been restructuring its operations following legal settlements.
The standout performer was SUBLOCADE, Indivior's long-acting injectable treatment for opioid use disorder, which generated quarterly revenue of $252 million, a 30% increase year-over-year. For the full year 2025, SUBLOCALE achieved record revenue of $856 million, representing 13% growth from the previous year.
"We delivered a strong fourth quarter and full year 2025, driven by continued momentum in our U.S. SUBLOCADE business," the company stated in its earnings announcement. Adjusted EBITDA surged 91% year-over-year to $142 million in the fourth quarter, while full-year adjusted EBITDA increased 20% to $428 million.
The company's board approved a new share repurchase authorization of up to $400 million, with a term of up to 18 months. Repurchases will be made opportunistically from available cash, signaling management's confidence in the company's financial position and future prospects. This move comes just weeks after Indivior was added to the S&P SmallCap 600 index in December 2025, a development that analysts expected would increase institutional investor interest and liquidity.
For 2026, Indivior reaffirmed guidance for net revenue between $1.125 billion and $1.195 billion, with adjusted EBITDA projected at $535 million to $575 million. The forecast assumes SUBLOCADE revenue of $905 million to $945 million, representing 11% growth at the midpoint of guidance, supported by at least $150 million in annual non-GAAP operating expense savings.
The outlook comes amid favorable market conditions for opioid use disorder treatments. The global OUD treatment market is projected to grow from an estimated $7.15 billion in 2025 to approximately $11.55 billion by 2031, representing a compound annual growth rate of 7.25%, according to market research. Growth drivers include rising prevalence of opioid dependence, supportive government initiatives including elimination of the DATA-2000 waiver, expanded insurance coverage, and innovations in long-acting injectable formulations.
Analysts have responded positively to Indivior's trajectory. HC Wainwright raised its price target from $35 to $48 in January, maintaining a buy rating, while Northland Securities set a target of $50. Piper Sandler reiterated an overweight rating and increased its target to $41 from $27 last October. The consensus price target among seven analysts stands at $45.57, suggesting significant upside from current levels.
Indivior's transformation from a company grappling with legal challenges to a growth-focused pharmaceutical player is reflected in its stock performance. Shares have surged from a 52-week low of $8.34, now trading around $33.63 with a market capitalization of $4.13 billion. Institutional ownership stands at 86.8%, indicating strong confidence from professional investors following its index inclusion.
The company's focus on SUBLOCADE, which now represents the majority of its revenue, positions Indivior to capitalize on the expanding opioid treatment market. The long-acting injectable formulation addresses patient adherence challenges in medication-assisted treatment, a critical factor in managing opioid use disorder effectively.
With the new buyback program, record SUBLOCADE sales, and analyst upgrades pointing to continued growth, Indivior appears to have successfully navigated its restructuring period and established itself as a key player in the evolving opioid use disorder treatment landscape.